RG 6061

Drug Profile

RG 6061

Alternative Names: EZN-2968; RG6061; RO-7070179; SPC-2968

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santaris Pharma
  • Developer Enzon Pharmaceuticals; Roche
  • Class Antineoplastics; Antisense oligoribonucleotides
  • Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver cancer; Lymphoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Jan 2018 Roche completes a phase I trial in liver cancer (Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT02564614)
  • 07 Aug 2017 Discontinued - Phase-I for Lymphoma in USA (IV) (Roche pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top